FDA approval information for Epirubicin
Epirubicin was approved for use in the United States in 1999. Current indications are limited to use in patients with breast cancer who have evidence of lymph node involvement after primary resection of the breast tumor.
Dosage and administration for Epirubicin
Epirubicin is available as a solution generically and under the brand name Ellence in single use vials containing 50 or 200 mg [2 mg/mL]. The dose of epirubicin is typically 60 to 100 mg per meter squared given in combination with cyclophosphamide and fluorouracil. It is administered by slow intravenous infusion on days 1 and 8 of 28 day cycles.
Side effects of Epirubicin
Common side effects are similar to those of doxorubicin and include cardiac toxicity and secondary malignancies.